MedTrace Logo

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

NCT01364090 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to treatment early on.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Pegylated interferon alfa 2b

Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.

DRUG

Ribavirin

Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.

Sponsors & Collaborators

Principal Investigators

  • Gregory Dore, MBBS, PhD · University of New South Wales

  • Olav Dalgard, MD PhD · University Hospital, Akershus

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-06-30
Completion
2015-10-31

Countries

  • Australia
  • Belgium
  • Canada
  • Germany
  • Norway
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01364090 on ClinicalTrials.gov